Literature DB >> 12643108

Treatments for diabetic neuropathy.

A J Boulton1.   

Abstract

The management of symptomatic diabetic sensory neuropathy presents a therapeutic challenge to the practicing physician. Two approaches are outlined in this article. First, symptomatic therapies, which will not influence the natural history of painful neuropathy, are discussed. These include, in addition to the stable glycemic control, tricyclic drugs, a number of anticonvulsant and antiarrhythmic agents, and opioid-like medications. Topical therapies and nonpharmalogic approaches are also discussed. With the exception of near normoglycemia, treatments that may slow the progression of neuropathy are experimental and include aldose reductase inhibitors, antioxidants, and other agents. Finally, the approach to patients without symptoms but with sensory loss is discussed.

Entities:  

Mesh:

Substances:

Year:  2001        PMID: 12643108     DOI: 10.1007/s11892-001-0024-8

Source DB:  PubMed          Journal:  Curr Diab Rep        ISSN: 1534-4827            Impact factor:   4.810


  30 in total

Review 1.  The diabetic foot: the scope of the problem.

Authors:  A J Boulton; L Vileikyte
Journal:  J Fam Pract       Date:  2000-11       Impact factor: 0.493

Review 2.  Alpha-lipoic acid in the treatment of diabetic polyneuropathy in Germany: current evidence from clinical trials.

Authors:  D Ziegler; M Reljanovic; H Mehnert; F A Gries
Journal:  Exp Clin Endocrinol Diabetes       Date:  1999       Impact factor: 2.949

3.  Glycemic control is related to the morphological severity of diabetic sensorimotor polyneuropathy.

Authors:  B A Perkins; D A Greene; V Bril
Journal:  Diabetes Care       Date:  2001-04       Impact factor: 19.112

4.  New ulceration, new major amputation, and survival rates in diabetic subjects hospitalized for foot ulceration from 1990 to 1993: a 6.5-year follow-up.

Authors:  E Faglia; F Favales; A Morabito
Journal:  Diabetes Care       Date:  2001-01       Impact factor: 19.112

Review 5.  Pathophysiology and treatment of diabetic neuropathy.

Authors:  A Dejgaard
Journal:  Diabet Med       Date:  1998-02       Impact factor: 4.359

6.  Benefits of a multidisciplinary approach in the management of recurrent diabetic foot ulceration in Lithuania: a prospective study.

Authors:  V Dargis; O Pantelejeva; A Jonushaite; L Vileikyte; A J Boulton
Journal:  Diabetes Care       Date:  1999-09       Impact factor: 19.112

7.  Gabapentin for the symptomatic treatment of painful neuropathy in patients with diabetes mellitus: a randomized controlled trial.

Authors:  M Backonja; A Beydoun; K R Edwards; S L Schwartz; V Fonseca; M Hes; L LaMoreaux; E Garofalo
Journal:  JAMA       Date:  1998-12-02       Impact factor: 56.272

8.  Intensive blood-glucose control with sulphonylureas or insulin compared with conventional treatment and risk of complications in patients with type 2 diabetes (UKPDS 33). UK Prospective Diabetes Study (UKPDS) Group.

Authors: 
Journal:  Lancet       Date:  1998-09-12       Impact factor: 79.321

9.  Double-blind randomized trial of tramadol for the treatment of the pain of diabetic neuropathy.

Authors:  Y Harati; C Gooch; M Swenson; S Edelman; D Greene; P Raskin; P Donofrio; D Cornblath; R Sachdeo; C O Siu; M Kamin
Journal:  Neurology       Date:  1998-06       Impact factor: 9.910

10.  Guidelines for the diagnosis and outpatient management of diabetic peripheral neuropathy.

Authors:  A J Boulton; F A Gries; J A Jervell
Journal:  Diabet Med       Date:  1998-06       Impact factor: 4.359

View more
  4 in total

1.  [Colorectal cancer 2D-proteomics: identification of altered protein expression].

Authors:  G S Krasnov; N Iu Oparina; S L Khankin; T D Mashkova; A N Ershov; O G Zatsepina; V L Karpov; S F Beresten'
Journal:  Mol Biol (Mosk)       Date:  2009 Mar-Apr

Review 2.  Update on the pathogenesis of diabetic neuropathy.

Authors:  Irina G Obrosova
Journal:  Curr Diab Rep       Date:  2003-12       Impact factor: 5.430

3.  Stratified analyses for selecting appropriate target patients with diabetic peripheral neuropathy for long-term treatment with an aldose reductase inhibitor, epalrestat.

Authors:  N Hotta; R Kawamori; Y Atsumi; M Baba; H Kishikawa; J Nakamura; S Oikawa; N Yamada; H Yasuda; Y Shigeta
Journal:  Diabet Med       Date:  2008-07       Impact factor: 4.359

4.  Epalrestat, an aldose reductase inhibitor, in diabetic neuropathy: an Indian perspective.

Authors:  S R Sharma; Nalini Sharma
Journal:  Ann Indian Acad Neurol       Date:  2008-10       Impact factor: 1.383

  4 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.